Furthermore, the dynamic changes of intestinal microbiota have a highly significant linkage to the efficacy of PD-1 inhibitor treatment [15] .
← all excerpts
Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy.
1
—
—